Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 2 relevant ethics committee: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
Gxplex admin (talk | contribs) m 1 revision imported |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{ReferenceData | ||
| | |has_document=Document:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 | ||
| | |module=1 | ||
| | |unit=1.5.3 | ||
|scope=HM | |||
|doc_part=Article 2 | |||
relevant ethics committee | relevant ethics committee | ||
| | |language=EN | ||
| | |entry_by=Florian Adragna | ||
| | |contributors= | ||
| | |tags=TAG-00134-Eth-kom ++ TAG-00244-Def-ini ++ TAG-00008-Cli-ngK | ||
|tags_display=[[Glossary:TAG-00134-Eth-kom|Ethics committee]], [[Glossary:TAG-00244-Def-ini|Definition]], [[Glossary:TAG-00008-Cli-ngK|Clinical trial]] | |||
|comment=Definition of relevant ethics committee in the context of a clinical trial | |||
|content=[…] | |||
|- | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
= | |||
[…] | |||
“relevant ethics committee”, in relation to a clinical trial, means— | “relevant ethics committee”, in relation to a clinical trial, means— | ||
(a)in a case where an ethics committee has given a favourable opinion in relation to that trial and paragraph 13 of Schedule 2 applies, the ethics committee which is the relevant ethics committee for that trial by virtue of sub-paragraph (5) of that paragraph; | (a)in a case where an ethics committee has given a favourable opinion in relation to that trial and paragraph 13 of Schedule 2 applies, the ethics committee which is the relevant ethics committee for that trial by virtue of sub-paragraph (5) of that paragraph; | ||
| Line 52: | Line 18: | ||
(c)in any other case, the ethics committee which has given a favourable opinion in relation to that trial in accordance with regulation 15; | (c)in any other case, the ethics committee which has given a favourable opinion in relation to that trial in accordance with regulation 15; | ||
[...] | [...] | ||
}} | |||
Latest revision as of 13:49, 16 July 2026
| Document information | |
|---|---|
| Reference | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| Validity area | GBR |
| Scope(s) | HM |
| Document name | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Version / Revision | 01-May-2004 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 1 — Unit 1.5.3 |
| Scope | HM |
| Document part | Article 2
relevant ethics committee |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Ethics committee, Definition, Clinical trial |
Content
[…] “relevant ethics committee”, in relation to a clinical trial, means— (a)in a case where an ethics committee has given a favourable opinion in relation to that trial and paragraph 13 of Schedule 2 applies, the ethics committee which is the relevant ethics committee for that trial by virtue of sub-paragraph (5) of that paragraph; (b)in a case where an ethics committee has given an unfavourable opinion in relation to that trial but a favourable opinion has been given by an appeal panel in accordance with paragraph 4(4) of Schedule 4, that committee, or (c)in any other case, the ethics committee which has given a favourable opinion in relation to that trial in accordance with regulation 15; [...]
